In last trading session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw 0.83 million shares changing hands with its beta currently measuring 0.71. Company’s recent per share price level of $2.85 trading at -$0.14 or -4.68% at ring of the bell on the day assigns it a market valuation of $194.19M. That closing price of CRVS’s stock is at a discount of -250.88% from its 52-week high price of $10.00 and is indicating a premium of 54.39% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.96 million shares which gives us an average trading volume of 604.60K if we extend that period to 3-months.
For Corvus Pharmaceuticals Inc (CRVS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Upright in the red during last session for losing -4.68%, in the last five days CRVS remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $2.85 price level, adding 16.91% to its value on the day. Corvus Pharmaceuticals Inc’s shares saw a change of -46.73% in year-to-date performance and have moved -15.68% in past 5-day. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) showed a performance of -34.93% in past 30-days. Number of shares sold short was 5.39 million shares which calculate 8.39 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12.5 to the stock, which implies a rise of 77.2% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -321.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -321.05% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.47% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 50.00% while estimates for its earnings growth in next 5 years are of 46.07%.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Insiders are in possession of 3.25% of company’s total shares while institution are holding 55.43 percent of that, with stock having share float percentage of 57.29%. Investors also watch the number of corporate investors in a company very closely, which is 55.43% institutions for Corvus Pharmaceuticals Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at CRVS for having 6.94 million shares of worth $12.64 million. And as of 2024-06-30, it was holding 11.6289 of the company’s outstanding shares.
The second largest institutional holder is SAMLYN CAPITAL, LLC, which was holding about 6.12 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.2546 of outstanding shares, having a total worth of $11.14 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.58 shares of worth $4.51 million or 2.32% of the total outstanding shares. The later fund manager was in possession of 793.14 shares on Dec 31, 2024 , making its stake of worth around $2.26 million in the company or a holder of 1.16% of company’s stock.
